Owing to the potential limitations of CD33 as a target antigen in AML and concerns over antigen escape, additional IL-15-containing NK cell engagers for AML are also under preclinical evaluation, including a molecule with a humanized anti-CD16 heavy chain camelid single domain antibody and a single-chain variable fragment targeting human CLEC12A [48]. This evidence concerns the gene FCGR3A and acute myeloid leukemia.